Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9472908 | 0.91 | ATM (0.45) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL9058778 | 0.91 | ATM (0.45) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL7397628 | 0.90 | ATM (0.44) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL8270815 | 0.89 | ATM (0.43) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL6836252 | 0.89 | ATM (0.43) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL7443701 | 0.88 | ATM (0.46) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL9005035 | 0.88 | ATM (0.46) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL7432732 | 0.88 | ATM (0.46) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL6312228 | 0.88 | ATM (0.46) | ATMCTSSCTSLCTSBCTSK | |
| SCHEMBL8270814 | 0.88 | KLK7 (0.45) | ATMCTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | ATM 4344/4885CTSS 3882/4885CTSL 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.